Satiety effects of the type A CCK receptor antagonist LOXIGLUMIDE (cas 107097-80-3) in lean and obese women

Add time:08/15/2019    Source:sciencedirect.com

Several studies have demonstrated that administration of cholecystokinin (CCK) reduces food intake in several species, including humans. In animal studies CCK-receptor antagonists have been reported to increase food intake, suggesting a physiological satiety effect of CCK in these animals. In a double-blind, placebo-controlled study, we investigated the effect of the specific CCK-A receptor antagonist LOXIGLUMIDE (cas 107097-80-3) on food intake (carbohydrate-rich meal) and on subjective hunger feelings scored with visual analogue scales and food selection lists in seven healthy obese women and in seven healthy lean women. Loxiglumide was administered intravenously in a dose of 10 mg/kg ideal weight/h. For the whole group, food intake during loxiglumide (359 ± 39 g) was not significantly different from food intake during saline infusion (333 ± 31 g). Also, when the lean and obese subgroups were analyzed separately, no significant influence of loxiglumide on food intake was found. In addition, no significant differences in satiety scores were seen using the food selection lists or visual analogue scales. In conclusion, in the present study during infusing the CCK-A receptor antagonist loxiglumide we found no increase in preprandial satiety nor in food intake of a carbohydrate-rich meal nor in postprandial satiety in lean and obese women.

We also recommend Trading Suppliers and Manufacturers of LOXIGLUMIDE (cas 107097-80-3). Pls Click Website Link as below: cas 107097-80-3 suppliers

Prev:Treatment with cholecystokinin receptor antagonist LOXIGLUMIDE (cas 107097-80-3) enhances insulin response to intravenous glucose stimulation in postpancreatitic rats
Next:LOXIGLUMIDE (cas 107097-80-3) inhibits cholecystokinin stimulated somatostatin secretion and simultaneously enhances gastric acid secretion in humans)